Business Context and Reporting Period
Company: BioCancell Ltd. (formerly BioCancell Therapeutics Inc.)
Filing Type: Form 6-K (Translation of Quarterly Report)
Reporting Period: Six months ended June 30, 2012
Business Overview: The Company is a biotechnology firm engaged in the research and development of cancer drugs, specifically BC-819, a plasmid-based therapy targeting bladder, pancreatic, and ovarian cancers. The financial statements are presented on a pro forma basis to reflect a reverse merger completed on August 14, 2012, between the Israeli shell company BioCancell Ltd. and the operating US subsidiary BioCancell Therapeutics Inc.
Key Financial Metrics (Pro Forma)
| Metric (NIS Thousands) | Six Months Ended June 30, 2012 |
Six Months Ended June 30, 2011 |
As of June 30, 2012 (Balance Sheet) |
|---|---|---|---|
| Revenue | 0 | 0 | N/A |
| Net Loss | (15,695) | (9,091) | N/A |
| Operating Loss | (11,720) | (8,645) | N/A |
| Net Financing Expenses (Income) | (3,975) | 446 | N/A |
| Cash and Cash Equivalents | N/A | N/A | 1,428 |
| Total Current Assets | N/A | N/A | 2,404 |
| Total Current Liabilities | N/A | N/A | 19,838 |
| Stockholders' Deficit | N/A | N/A | (18,186) |
| Convertible Notes Payable | N/A | N/A | 13,345 |
Note: All figures are in NIS thousands. The company has no revenue as it is in the pre-commercial development stage.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the six months ended June 30, 2012, increased to NIS 15.7 million from NIS 9.1 million in the prior year period. This was driven by higher R&D costs and significant non-cash financing expenses.
- R&D Expenses: Net R&D expenses rose 71.2% to NIS 8.3 million (from NIS 4.9 million), primarily due to the progression of Phase IIb clinical trials for pancreatic and bladder cancer.
- Financing Expenses: Net financing expenses increased significantly to NIS 4.0 million (from NIS 0.4 million income). This is largely due to fair value adjustments on convertible notes and warrants, reflecting changes in the company's stock price and volatility.
- Liquidity Position: Current liabilities increased to NIS 19.8 million (from NIS 16.1 million at year-end 2011), while current assets decreased to NIS 2.4 million, resulting in a negative working capital of NIS 17.4 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Risk: The filing explicitly states there is "significant doubt" regarding the Company's ability to continue as a going concern. Management believes current financing is sufficient only until September 2012. Continued operations depend on raising additional capital.
- Clinical Trial Progress:
- Bladder Cancer: Phase IIb trial results indicated that 63% of patients (19 out of 30) avoided tumor recurrence at the 3-month mark, meeting the primary endpoint criteria.
- Pancreatic Cancer: Phase IIb trial is ongoing with 8 patients treated; results for 12 patients expected by year-end.
- Ovarian Cancer: Phase I/IIa trial is ongoing.
- Capital Raising Activities:
- Completed a private placement in January 2012 raising NIS 11.1 million.
- Subsequent to the balance sheet date (July 2012), Clal Biotechnology Industries Ltd. (CBI) invested $2.48 million to repay a convertible loan from Tikcro Technologies Ltd.
- Convertible loans from 2008 were converted to shares in July 2012.
- A new loan of NIS 2 million from CBI was secured in August 2012.
- Corporate Governance Changes:
- CEO Uri Danon resigned in June 2012; Jonathan Burgin is the current CEO.
- Dr. Aharon Schwartz was appointed Chairman of the Board in May 2012.
- Director Aviv Boim resigned in August 2012.
- Listing Status: The Tel Aviv Stock Exchange (TASE) issued a warning regarding non-compliance with listing rules, granting an extension until December 31, 2012, to avoid transfer to the preservation list.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the NIS 1.4 million cash balance and the NIS 2 million CBI loan to sustain operations beyond September 2012.
- Convertible Debt Conversion: Confirm the final terms and share count resulting from the July 2012 conversion of 2008 convertible loans and the CBI investment.
- Clinical Trial Final Data: Monitor the final statistical analysis of the bladder cancer Phase IIb trial (39 patients total) to confirm the efficacy claims made in the interim report.
- Listing Compliance: Track the Company's progress in meeting TASE listing requirements by the December 31, 2012 deadline.
- Future Capital Raise: Assess the status of the draft prospectus for a public offering mentioned in the filing to determine if additional equity financing is imminent.